Roggwil, November 10, 2020 – The sales of the tinnitus therapy device tinniwell have multiplied in 2020 compared to last year. The delivery of the 3rd series took place last month, and due to the high demand, production of the 4th series has now begun. The reason for this development is, on the one hand, the high recommendation rate from cured former patients, as well as the complete digitalization of sales. To meet the growing challenges, a new CRM system (Customer Relationship Management) has been migrated. With the Salesforce solution from the USA, the increased requirements of sales and the regulations of medical device regulation under MDR can now be met.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been marketing a tinnitus therapy device under the name tinniwell since 2016. Other sales companies include Resaphene Deutschland GmbH in Constance, Resaphene UK Ltd. in London, and Resaphene US LLC in the USA.

++ Contact for inquiries:

Resaphene Suisse AG

Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5

9322 Egnach

Switzerland
T. +41 714500668

a.rauterkus@resaphene.ch